A TRiKE CAM1615HER2, which contains a VHH targeting CD16a, an scFv for HER2 and IL-15, shows an increase in NK cell proliferation and activation in vitro and tumor clearance in vivo (116). The gene discussed is FCGR3A; the disease is neoplasm.